Viswanadhan Krishnan

SEC source: 0001439222-26-000091 · wk-form4_1782249510.xml · derivative · entry 2

Viswanadhan Krishnan · CIK 0001999913 · Chief Strategy and Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,000

Underlying: Common stock · 3,000 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2 · derivative.exercise_date: Performance stock units were granted on March 5, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service.

F2 · derivative.expiration_date: Performance stock units were granted on March 5, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service.

SEC source: 0001439222-26-000091 · wk-form4_1782249510.xml · derivative · entry 1

Viswanadhan Krishnan · CIK 0001999913 · Chief Strategy and Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common stock · 3,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of the issuer's common stock.

F2 · derivative.exercise_date: Performance stock units were granted on March 5, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service.

F2 · derivative.expiration_date: Performance stock units were granted on March 5, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service.

SEC source: 0001439222-26-000059 · wk-form4_1775505928.xml · derivative · entry 3

Viswanadhan Krishnan · CIK 0001999913 · Chief Corp Dev & Strategy

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,100

Underlying: Common stock · 8,100 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock.

F3 · derivative.exercise_date: The PSUs were granted on March 5, 2025. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F3 · derivative.expiration_date: The PSUs were granted on March 5, 2025. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

SEC source: 0001439222-26-000059 · wk-form4_1775505928.xml · nonDerivative · entry 2

Viswanadhan Krishnan · CIK 0001999913 · Chief Corp Dev & Strategy

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,282

F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 5, 2025.

SEC source: 0001439222-26-000059 · wk-form4_1775505928.xml · nonDerivative · entry 1

Viswanadhan Krishnan · CIK 0001999913 · Chief Corp Dev & Strategy

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,241

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001439222-26-000049 · wk-form4_1773087128.xml · derivative · entry 3

Viswanadhan Krishnan · CIK 0001999913 · Chief Corp Dev & Strategy

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,200

Underlying: Common stock · 8,100 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units were granted on March 5, 2025. Beginning on March 5, 2026, the shares underlying the restricted stock units will vest in three equal annual installments.

F3 · derivative.expiration_date: The restricted stock units were granted on March 5, 2025. Beginning on March 5, 2026, the shares underlying the restricted stock units will vest in three equal annual installments.

SEC source: 0001439222-26-000049 · wk-form4_1773087128.xml · nonDerivative · entry 2

Viswanadhan Krishnan · CIK 0001999913 · Chief Corp Dev & Strategy

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,141

F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 5, 2025.

SEC source: 0001439222-26-000049 · wk-form4_1773087128.xml · nonDerivative · entry 1

Viswanadhan Krishnan · CIK 0001999913 · Chief Corp Dev & Strategy

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,100

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001439222-26-000032 · wk-form4_1772572279.xml · derivative · entry 2

Viswanadhan Krishnan · CIK 0001999913 · Chief Corp Dev & Strategy

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,000

Underlying: Common stock · 52,000 shares

Expires 2036-03-01

F3 · derivative.exercise_date: This option was granted on March 1, 2026. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001439222-26-000032 · wk-form4_1772572279.xml · derivative · entry 1

Viswanadhan Krishnan · CIK 0001999913 · Chief Corp Dev & Strategy

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common stock · 14,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2 · derivative.exercise_date: The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments.

F2 · derivative.expiration_date: The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments.

SEC source: 0001610717-25-000304 · form4.xml · derivative · entry 2

Viswanadhan Krishnan · CIK 0001999913 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2035-06-17

F1 · price: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2]

F2 · price: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]

F3 · price: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration.

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2]

F2 · derivative.exercise_date: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]

F3 · derivative.exercise_date: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration.

SEC source: 0001610717-25-000304 · form4.xml · derivative · entry 1

Viswanadhan Krishnan · CIK 0001999913 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,173 shares

Expires 2032-10-26

F1 · price: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2]

F2 · price: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]

F3 · price: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration.

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2]

F2 · derivative.exercise_date: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]

F3 · derivative.exercise_date: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration.

SEC source: 0001610717-25-000251 · form4.xml · derivative · entry 1

Viswanadhan Krishnan · CIK 0001999913 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2035-06-17

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) the one year anniversary of June 18, 2025 or (ii) the next Annual Meeting following June 18, 2025, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001439222-25-000027 · wk-form4_1741382325.xml · derivative · entry 2

Viswanadhan Krishnan · CIK 0001999913 · Chief Corp Dev & Strategy

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,374

Underlying: Common stock · 55,374 shares

Expires 2035-03-05

F3 · derivative.exercise_date: This option was granted on March 5, 2025. The shares underlying this option vest as to 25% of the underlying shares on March 5, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001439222-25-000027 · wk-form4_1741382325.xml · derivative · entry 1

Viswanadhan Krishnan · CIK 0001999913 · Chief Corp Dev & Strategy

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,300

Underlying: Common stock · 24,300 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2 · derivative.exercise_date: The restricted stock units were granted on March 5, 2025. Beginning on March 5, 2026, the shares underlying the restricted stock units will vest in three equal annual installments.

F2 · derivative.expiration_date: The restricted stock units were granted on March 5, 2025. Beginning on March 5, 2026, the shares underlying the restricted stock units will vest in three equal annual installments.

SEC source: 0001610717-24-000301 · form4.xml · derivative · entry 1

Viswanadhan Krishnan · CIK 0001999913 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,742

Underlying: Common Stock · 23,742 shares

Expires 2034-06-03

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 4, 2024 (the "Vesting Commencement Date") or (ii) the next Annual Meeting following June 4, 2024, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001610717-23-000346 · form4.xml · derivative · entry 1

Viswanadhan Krishnan · CIK 0001999913 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2033-11-08

F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from November 10, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date.